Global epigenetic therapies market to increase at a CAGR of 10% through 2017
The global epigenetic therapies market is expected to reach a total value of around $2.518 billion by the end of 2013, with the industry forecast to increase at a compound annual growth rate (CAGR) of over 10% through to 2017, according to a new report added to the offering of companiesandmarkets.com.
Throughout the next decade, epigenetic therapies will be the largest sector of the world epigenetics market, accounting for more than half of revenues in 2023. In 2011, Celgene's (Nasdaq: CELG) Vidaza (azacitidine) led the market, with revenue of $705 million. Patent expiries and generic launches will affect three of the four currently-marketed therapies by the middle of this decade.
New products to drive growth
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze